The medtech company Pexa's rights issue was subscribed for approximately 272 percent and provides the company with approximately SEK 9.9 million before issue costs.Against the background of the oversubscription, the board has decided on an over-allotment issue of approximately SEK 6.3 million on the same terms as the rights issue.The rights issue comprises 31.0 million new B shares, while the over-allotment issue comprises 19.7 million B shares. Trading in paid subscribed shares (BTA) is expected to continue until the rights issue has been registered with the Swedish Companies Registration Office, which is expected to take place around August 6.Together with the previously announced directed issue to Hallberg Management of SEK 10 million, Pexa thus receives a total of approximately SEK 26 million before issue costs."It is clear proof of confidence in Pexa, our strategy and the potential we see in the company's continued development. The strengthened financial position gives us good conditions to continue implementing our strategic plans, drive our prioritized projects forward and create value as we take the next step in the company's development," says CEO Tomas Gustafsson.